Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.68 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955440 | 1.00 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9954673 | 0.88 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9954680 | 0.88 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9960770 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9953752 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL26198635 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL26198636 | 0.82 | PIK3CA (0.68) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9955527 | 0.82 | PIK3CA (0.73) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL15346551 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG | |
| SCHEMBL9955931 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3C3PIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | claimed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | claimed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | claimed |
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| EP-2655375-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085244-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | DPYD, TYMP, DHPS | PIK3CA 192/4885PIK3C3 1318/4885PIK3R1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.